...
首页> 外文期刊>American Journal of Physiology >Cardioprotective effects of carvedilol on acute autoimmune myocarditis: anti-inflammatory effects associated with antioxidant property.
【24h】

Cardioprotective effects of carvedilol on acute autoimmune myocarditis: anti-inflammatory effects associated with antioxidant property.

机译:卡维地洛对急性自身免疫性心肌炎的心脏保护作用:与抗氧化性质相关的抗炎作用。

获取原文
获取原文并翻译 | 示例

摘要

Carvedilol, a new beta-blocker with antioxidant properties, has been shown to be cardioprotective in experimental models of myocardial damage. We investigated whether carvedilol protects against experimental autoimmune myocarditis (EAM) because of its suppression of inflammatory cytokines and its antioxidant properties. We orally administered a vehicle, various doses of carvedilol, racemic carvedilol [R(+)-carvedilol, an enantiomer of carvedilol without beta-blocking activity], metoprolol, or propranolol to rats with EAM induced by porcine myosin for 3 wk. Echocardiographic study showed that the three beta-blockers, except R(+)-carvedilol, suppressed left ventricular fractional shortening and decreased heart rates to the same extent. Carvedilol and R(+)-carvedilol, but not metoprolol or propranolol, markedly reduced the severity of myocarditis at the two different doses and suppressed thickening of the left ventricular posterior wall in rats with EAM. Only carvedilol suppressed myocardial mRNA expression of inflammatory cytokines and IL-1beta protein expression in myocarditis. In addition, carvedilol and R(+)-carvedilol decreased myocardial protein carbonyl contents and myocardial thiobarbituric acid-reactive substance products in rats with EAM. The in vitro study showed that carvedilol and R(+)-carvedilol suppressed IL-1beta production in LPS-stimulated U937 cells and that carvedilol and R(+)-carvedilol, but not metoprolol or propranolol, suppressed thiobarbituric acid-reactive substance products in myocardial membrane challenged by oxidative stress. It was also confirmed that probucol, an antioxidant, ameliorated EAM in vivo. Carvedilol protects against acute EAM in rats, and the superior cardioprotective effect of carvedilol compared with metoprolol and propranolol may be due to suppression of inflammatory cytokines associated with the antioxidant properties in addition to the hemodynamic modifications.
机译:卡维地洛是一种具有抗氧化性能的新型β受体阻滞剂,已在心肌损伤的实验模型中显示出心脏保护作用。我们调查了卡维地洛是否能够抑制实验性自身免疫性心肌炎(EAM),因为它能抑制炎症性细胞因子及其抗氧化特性。我们向猪肌球蛋白诱导的EAM大鼠连续3周口服了一种载剂,各种剂量的卡维地洛,消旋卡维地洛[R(+)-卡维地洛,卡维地洛的对映异构体,无β阻断活性],美托洛尔或普萘洛尔。超声心动图研究表明,除R(+)-卡维地洛外,三种β受体阻滞剂均抑制左心室分数缩短,并以相同程度降低心率。卡维地洛和R(+)-卡维地洛,但不是美托洛尔或普萘洛尔,可显着降低两种不同剂量的心肌炎的严重程度,并抑制了EAM大鼠的左心室后壁增厚。在心肌炎中,只有卡维地洛抑制了心肌炎性细胞因子的mRNA表达和IL-1beta蛋白的表达。此外,卡维地洛和R(+)-卡维地洛降低了EAM大鼠的心肌蛋白羰基含量和心肌硫代巴比妥酸反应性物质产物。体外研究显示卡维地洛和R(+)-卡维地洛抑制LPS刺激的U937细胞中IL-1β的产生,卡维地洛和R(+)-卡维地洛可抑制美托洛尔或普萘洛尔抑制硫代巴比妥酸反应性物质产物心肌膜受到氧化应激的挑战。还证实抗氧化剂普罗布考改善了体内EAM。卡维地洛可预防大鼠急性EAM,卡维地洛与美托洛尔和普萘洛尔相比具有更好的心脏保护作用,这可能是由于除具有血流动力学修饰外,还抑制了与抗氧化剂相关的炎性细胞因子。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号